Who is sponsoring NCT02591238?

NCT02591238 is sponsored by Peking Union Medical College Hospital.

What condition does NCT02591238 study?

NCT02591238 studies Smoking, Vascular System Injuries.

What drugs are being tested in NCT02591238?

Interventions: non-smoker oral placebo, non-smoker oral melatonin, smoker oral placebo, smoker oral melatonin.

What is the status of NCT02591238?

NCT02591238 is currently COMPLETED.

Last reviewed 2016-02-03 · How we verify

The Protective Effect of Melatonin on Smoke-induced Vascular Injury in Human

NCT02591238 Phase 4 COMPLETED Results posted

The main purpose of this study was to evaluate the effects of melatonin in the regulation of the vascular injury in smokers through population-based, randomized, double-blind, placebo-controlled trial.

Details

Lead sponsor	Peking Union Medical College Hospital
Phase	Phase 4
Status	COMPLETED
Enrolment	68
Start date	2015-06
Completion	2015-10

Conditions

Smoking
Vascular System Injuries

Interventions

non-smoker oral placebo
non-smoker oral melatonin
smoker oral placebo
smoker oral melatonin

Primary outcomes

Smoke-induced Vascular Injury and Melatonin's Effect in This Process Assessed by the Concentration of Fbg. — Three months
Smoke-induced Vascular Injury and Melatonin's Effect in This Process Assessed by the Concentration of Glu. — Three months.
Smoke-induced Vascular Injury and Melatonin's Effect in This Process Assessed by the Concentration of FFA. — Three months.
Smoke-induced Vascular Injury and Melatonin's Effect in This Process Assessed by the Concentration of TC. — Three months.
Smoke-induced Vascular Injury and Melatonin's Effect in This Process Assessed by the Concentration of TG. — Three months.
Smoke-induced Vascular Injury and Melatonin's Effect in This Process Assessed by the Concentration of LDL-C. — Three months.

Countries

China